U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
INVOKANA® is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events
Approval aligns with ADA and AACE treatment guidance and supports use of INVOKANA® across a broad range of patients
TITUSVILLE, N.J.,... Biopharmaceuticals, Endocrinology, Cardiology, FDA Janssen Pharmaceutical, INVOKANA, canagliflozin, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Invokana | Pharmaceuticals | Stroke